Diabetes

GLP-1 sees strong return dosage in China and Japan as India lags on value

Global drugmakers are prioritising China and Japan for GLP-1 investments due to stronger pricing power and adoption, while India remains a large but price-sensitive market with slower premium uptake

Alembic Pharma receives USFDA approval for generic dapagliflozin tablets

Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US health regulator for its generic version of dapagliflozin tablets used to control blood sugar levels in people with type-2 diabetes. The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of dapagliflozin tablets of strengths 5 mg and 10 mg, Alembic Pharmaceuticals Ltd said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Farxiga Tablets, 5 mg and 10 mg, of AstraZeneca AB (AstraZeneca), it added. Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Dapagliflozin Tablets, 5 mg and 10 mg. With this approval, Alembic is eligible for 180 days of shared generic drug marketing exclusivity, the company said. Dapagliflozin tablet is indicated to reduce the risk of hospitalisation for heart failure in adults with ...

Cheap, accessible, powerful: The promise and peril of semaglutide in India

Cheap, accessible, and powerful semaglutide is changing India’s weight-loss and diabetes landscape. But as prices crash and access expands, the risks also increase

Govt issues guidelines on GLP-1 drugs use, risks, and regulations

To prevent unauthorised sale, unsupervised use, and other malpractices, the Drug Controller of India has intensified its regulatory surveillance, warning that the drugs can lead to serious side effect

Aurobindo gains 3%, stock hits 52-week high; JM Financial sees more upside

In the past one month, Aurobindo has outperformed the market by surging 9 per cent, as compared to 8.5 per cent decline in the BSE Sensex.

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Semaglutide prices crash up to 90% as 15+ generics launch in two days

Off-patent GLP-1 therapy drives 70-90% price drop with generics flooding in

Dr Reddy's enters semaglutide market, launches diabetes generic drug

Drugmaker expects to receive regulatory approval for weightloss sema generic in a few months

Semaglutide generics may fuel rush for cosmetic weight loss, warn doctors

As semaglutide goes off patent, doctors warn of misuse by non-obese individuals amid rising demand driven by social media and lower-cost generics

Delhi HC seeks response from Centre, CDSCO over misuse of diabetes drugs

These drugs, though approved for type 2 diabetes, have witnessed a surge in demand globally due to their weight-loss effects

Study links fathers' nicotine use to altered metabolism in children

A new mouse study suggests nicotine exposure in fathers before conception may alter how their children process sugar and metabolism, potentially raising diabetes risk in the next generation

GLP-1 drugs may fight addiction across every major substance: Study

Patients on GLP-1 drugs report losing cravings for addictions, ranging from opioids to gambling, prompting researchers to examine whether these diabetes and obesity medicines can curb addiction

Novo Nordisk, Abbott tie up to launch second Ozempic brand in India

Abbott will commercialise Extensior, a second semaglutide brand of Ozempic in India, as part of Novo Nordisk's strategy to expand access amid rising demand and looming patent expiry

Green vs brown coconut water: Which one is actually healthier for you?

As coconuts mature from green to brown, their sugar levels, electrolyte balance and metabolic impact shift, and doctors explain which version suits your health needs better

Eris Life partners Natco Pharma to launch semaglutide generic in India

Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as rising demand and impending patent expiry fuel intense competition in metabolic and weight-loss therapies

Thailand halves default sugar in cafes under a nationwide health push

Thailand has redefined 'normal sweetness' in cafe drinks, cutting default sugar by 50% in a nationwide health push aimed at reducing obesity, diabetes and excess sugar intake

Doctors flag risks of relying on HbA1c for diabetes diagnosis in India

Doctors warn that heavy reliance on HbA1c for diabetes diagnosis in India may lead to under- or over-diagnosis due to high anaemia and kidney disease burden, urging multiparametric testing

Why HbA1c, India's most trusted diabetes test, may be getting it wrong

A Lancet Regional Health-Southeast Asia study warns that HbA1c, the gold-standard diabetes test, can misdiagnose or delay diabetes in Indians due to widespread anaemia and blood disorders

Massive global study rewrites what we know about Type 2 diabetes biology

A large global genetics study shows Type 2 diabetes is driven by complex, tissue-specific biology across organs and populations, challenging blood-focused research and treatment strategies

Why more professionals in their 30s and 40s are turning pre-diabetic

Doctors say long sitting hours, stress-filled routines and late meals are fuelling a silent metabolic crisis in urban workplaces